|
Virtual Meetings 2021
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with ER-Positive Breast CancerFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Matthew P Goetz, MD Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD Professor of Oncology and Pharmacology Director, Mayo Clinic Breast SPORE Co-Leader, Women’s Cancer Program Mayo Clinic Rochester, Minnesota Komal Jhaveri, MD Assistant Attending Physician Breast Medicine Service/Department of Medicine Memorial Sloan Kettering Cancer Center Assistant Professor of Medicine Weill Cornell Medical College New York, New York Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment AB Alexander Distinguished Chair in Oncology Associate Director for Clinical Research Leader of the Breast Cancer Program UT Health San Antonio The University of Texas MD Anderson Cancer Center San Antonio, Texas Kevin Kalinsky, MD, MS Associate Professor Department of Hematology and Medical Oncology Emory University School of Medicine Director, Glenn Family Breast Center Director, Breast Medical Oncology Winship Cancer Institute of Emory University Atlanta, Georgia Ingrid A Mayer, MD, MSCI Professor of Medicine Ingram Professor of Cancer Research Co-Leader, VICC Breast Cancer Research Program Oncology Section Head, Division of Hematology/Oncology Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center Nashville, Tennessee Ruth O’Regan, MD Chair, Department of Medicine Charles A Dewey Professor of Medicine University of Rochester Rochester, New York SERIES MODERATOR Neil Love, MD Research To Practice Agenda
MODULE 1: Evolving Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer MODULE 2: Current Management of ER-Positive Metastatic Breast Cancer MODULE 3: Promising Investigational Strategies for Patients with ER-Positive Metastatic Breast Cancer
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Goetz — Consulting Agreements (Honoraria to Institution): AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Biovica, Blueprint Medicines, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc, Sermonix Pharmaceuticals; Contracted Research (to Institution): Lilly, Pfizer Inc, Sermonix Pharmaceuticals. Dr Jhaveri — Advisory Committee: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Jounce Therapeutics, Novartis, Pfizer Inc, Spectrum Pharmaceuticals Inc, Sun Pharma Advanced Research Company, Synthon, Taiho Oncology Inc; Contracted Research: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Lilly, Merck, Novartis, Novita Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Zymeworks. Dr Kaklamani — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Sanofi Genzyme; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc. Dr Kalinsky — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Cyclacel Pharmaceuticals Inc, Eisai Inc, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Seagen Inc; Speakers Bureau: Genentech, a member of the Roche Group, Immunomedics Inc. Dr Mayer — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cyclacel Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, Pfizer Inc. Dr O’Regan — Advisory Committee and Consulting Agreements: bioTheranostics Inc, Cyclacel Pharmaceuticals Inc, Lilly, MacroGenics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Contracted Research: Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Immunomedics Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from Exact Sciences Inc, Novartis and Sanofi Genzyme. |